1The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333: 1581-1587.
2Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Stroke Study (ECASS). JAMA,1995, 274: 1017-1025.
3Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA,2000, 283: 1145-1150.
4Madhavan R, Jacobs BS, Levine SR. Stroke trials: what have we learned? Neurol Res, 2002, 24Suppll : S27-S32.
5Elger B, Hornberger W, Schwarz M, et al. MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats. Eur J Pharmacol,1997, 336: 7-14.
6Hossmann V, Heiss WD, Bewermeyer H, et al. Controlled trial of ancrod in ischemic stroke. Arch Neurol, 1983, 40: 803-808.
7Olinger CP, Brott TG, Barsan WG, et al. Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med, 1998,17 : 1208-1209.
8The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke, 1994, 25: 1755-1759.
9Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke. JAMA, 2000, 283:2395 -2403.
10Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement.JAMA, 1996, 276: 637-639.
